Salah-Eddin Al-Batran, Director Institute of Clinical Research at University Cancer Center Franfkurt, shared a post on LinkedIn:
“Excited to share the publication of the IKF-s628/ MOONLIGHT trial in Nature Communications.
Our multi-cohort phase II study evaluated first-line immunotherapy strategies in advanced HER2-negative gastroesophageal adenocarcinoma (GEA), including dual checkpoint inhibition and triplet chemotherapy combinations
Key findings:
- Dual checkpoint blockade (nivolumab + ipilimumab) added to mFOLFOX.
Did not improve outcomes compared to chemotherapy alone.
Median PFS: 5.8 vs 6.6 months.
Median OS: 10.1 vs 12.5 months.
Higher grade ≥3 toxicities (74% vs 45%). - Short induction FOLFOX followed by immunotherapy (sequential strategy).
Inferior to continuous chemoimmunotherapy.
Median PFS: 4.0 months.
Median OS: 7.6 months. - FLOT + nivolumab (triplet chemotherapy + IO).
Encouraging activity and feasibility.
Median PFS: 7.0 months.
Median OS: 14.6 months.
ORR: 56%.
Particularly promising in PD-L1 positive tumors.
Grateful to the leading author Sylvie Lorenzen all investigators, study teams, and especially our patients and their families for their trust and contribution.”
Title: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
Authors: Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C. Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Nicolaas Dechow, Thomas Jens Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel Pink, Udo Lindig, Gunnar Folprecht, Gunter Schuch, Michael Bitzer, Volker Heinemann, Stefan Angermeier, Claus Bolling, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran
Read The Full Article
Other articles about Chemoimmunotherapy on OncoDaily.